Key findings relevant to injection site safety: Injection site reactions were not significantly higher in retatrutide groups compared to placebo The most common injection site reactions were transient redness and mild discomfort No participants discontinued due to injection site reactions The overall safety profile was consistent with other GLP-1 receptor agonists The more recent TRIUMPH-4 phase 3 trial confirmed these safety findings in a larger population
When glucose levels drop quickly, patients may face an increased risk of hypoglycemia if other medications are not adjusted in time
Keller, J., Beglinger, C., Holst, J
Stacking peptides for hair support Some researchers and practitioners combine multiple hair-supporting peptides for a synergistic effect
Their value lies in situations where metabolic dysfunction actively contributes to age-related decline
Education plays a critical role, as demonstrated by various randomized trials [72]